Depersonalization-derealization syndrome induced by reboxetine.
A high variety of factors have been implicated in the emergence of depersonalisation and derealisation episodes, including different drugs. A case abruptly induced by two applications of reboxetine, a selective and specific norepinephrine reuptake inhibitor, is reported occurring in a 50-year-old woman treated for a major depressive episode. The episode rapidly remitted after discontinuation of reboxetine. Previous data having indicated a role of the serotonin system in the pathophysiology of the phenomenon, a noradrenaline induced serotonin liberation of Raphe neurons is suggested as possible underlying mechanism.
Khazaal
Yasser
Y
University Department for Adult Psychiatry, Hôpital de Cery, Prilly-Lausanne, Switzerland. Yasser.Khazaal@hospvd.ch
Zullino
Daniele Fabio
DF
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003861:Depersonalization / Q000139:chemically induced*; D003866:Depressive Disorder / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects* / Q000627:therapeutic use; D000077593:Reboxetine
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D009025:Morpholines; D000077593:Reboxetine